At what enterprise value was LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES acquired in 2024?

During the acquisition of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES by SONIC HEALTHCARE in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES when it was acquired by SONIC HEALTHCARE?

The estimated EV/EBITDA multiple for LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES is in the range of 5x - 12x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES at the time of the deal?

The revenue of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES during the acquisition?

LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://investors.sonichealthcare.com/DownloadFile.axd?file=/Report/ComNews/20241209/02891934.pdf

← DATABASE

Home Database Healthcare & PharmaLADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES

12/2024

LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES acquired by SONIC HEALTHCARE

GERMANY Health Providers / Healthcare Facilities / Labs (Biology) EV 300M - 700M EUR

Context

Sonic Healthcare has signed binding agreements to acquire the LADR Laboratory Group, marking a substantial expansion of its German and European diagnostic footprint. The transaction was structured on a cash and debt-free basis, with a total consideration satisfied through a mix of Sonic ordinary shares (up to 222 million euros) and cash funded from existing facilities. The strategic rationale centers on the strong cultural and operational alignment between the two organizations, with significant synergy potential identified in procurement, laboratory overlaps, logistics, and equipment maintenance. The deal also includes an inherited put/call structure for a separate German laboratory business, expected to be fully consolidated by 2027. Following the acquisition, the target's senior leadership, including the CEO and Medical Director, will remain with the group to lead the integration collaboratively with the acquirer’s German division.

LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

LADR is one of the top five medical laboratory groups in Germany, providing high-quality diagnostic testing services through a national network of stand-alone and hospital-based laboratories. Founded in 1945 and managed by the third generation of the Kramer family, the group's business model is predominantly focused on medical laboratory revenue (80% of total), supplemented by medical supplies trading, logistical services, and a specialized clinical services division focused on women’s health. The group maintains a significant international footprint, including "badaj.to," the fourth largest laboratory group in Poland, and a joint-venture interest in Finland. Operating with over 2,800 full-time staff, LADR leverages a centralized laboratory hub in Geesthacht to provide comprehensive diagnostic solutions across the German healthcare landscape, emphasizing medical leadership and high-quality clinical outcomes.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
05/2025	FONDATION SANTE SERVICE	CLARIANE HAD (HOME HOSPITALIZATION SERVICES)	FRANCE	Health Providers	Clariane sells its French home hospitalization business to the leader of the sector in France, Fondation Sante Service. The deal is part of Clariane's EUR1bn asset disposal plan to strengthen its balance sheet
04/2025	EUROFINS SCIENTIFIC	SYNLAB SPAIN	SPAIN	Health Providers	Eurofins Scientific has completed the acquisition of 100% of SYNLAB’s clinical diagnostics operations in Spain. The transaction, initially agreed upon in October 2024, was finalized on March 31, 2025. This strategic carve-out allows SYNLAB to optimize its portfolio by exiting the Spanish market to focus on regions with higher strategic impact
12/2024	CAPZA	IMDEV	FRANCE	Health Providers	The transaction involves a primary Owner Buy-Out (OBO) where Capza and Bpifrance acquire a minority stake in Imdev to support its next phase of pan-European scaling. This capital injection includes a significant capital increase and a cash-out component for historical shareholders
11/2024	GROUPE IMAGERIE CARDINET	RADIOLOGIE PARIS OUEST	FRANCE	Health Providers	Groupe Imagerie Cardinet acquired 100% of Radiologie Paris Ouest from its previous majority shareholder, Azulis Capital, which had held a stake since 2019. The transaction was financed with the support of Andera Acto (Andera Partners' sponsorless/mezzanine arm), which had already invested in Cardinet in 2023
11/2024	WELLTOWER	CARE UK	UNITED KINGDOM	Health Providers	Bridgepoint divested its entire stake in Care UK to Welltower, a US healthcare REIT, marking the conclusion of approximately 14 years of private equity ownership. Bridgepoint had originally acquired Care UK in 2010 and had previously attempted an unsuccessful sale process, incurring £2
10/2024	QUALIUM	IMPC (IMAGERIE MEDICALE PARIS CENTRE)	FRANCE	Health Providers	Qualium Investissement is acquiring a 25% minority stake in IMPC from its associate radiologists. This primary LBO transaction follows a strategic period of reflection during which the founding doctors chose to maintain operational and capital control of their group rather than pursuing a majority sale
10/2024	MONTEFIORE INVESTMENT	DEMENEGO	ITALY	Health Providers	Montefiore Investment acquired a majority stake in Demenego from Vam Investments. This secondary LBO follows a highly successful four-year period of ownership by the seller, during which the company more than doubled its revenue and expanded its retail network from 15 to 39 stores
10/2024	ARDIAN	VISTA VISION	ITALY	Health Providers	Ardian Expansion acquired a majority stake in Vista Vision from its founders and Credem Private Equity. The transaction marks a new strategic phase for the group, following a period of rapid expansion where revenues tripled under Credem's tenure
08/2024	ORLANDO HEALTH	BROOKWOOD BAPTIST HEALTH SERVICES	UNITED STATES	Health Providers	Orlando Health signed a definitive agreement to acquire Tenet Healthcare's majority interest in Baptist Health, the faith-based integrated health system operating across Central Alabama. Upon closing, Orlando Health will become the majority and managing partner of Baptist Health, assuming day-to-day operational management of the system in partnership with Baptist Health System, which retains its minority stake and continues to anchor the organisation's faith-based mission
06/2024	L-GAM / CAPZA / IDIA CAPITAL INVESTISSEMENT	PSV GROUP	FRANCE	Health Providers	L-GAM, CAPZA, IDIA Capital Investissement, and Bpifrance are acquiring a minority stake in PSV Group from its associate physicians. The transaction allows for the entry of a consortium of minority financial partners while ensuring that the associate doctors, who remain majority shareholders, retain full operational and strategic control of the group

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LADR – LABORATORY GROUP DR. KRAMER & COLLEAGUES by SONIC HEALTHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).